口服足叶乙甙联合卡铂腹腔热灌注治疗多线化疗后复发性卵巢癌的临床研究

目的：探讨口服足叶乙甙联合卡铂腹腔热灌注治疗多线化疗后复发性卵巢癌的临床疗效及毒副作用。方法选择2010年1月至2013年8月我科收治的47例多线化疗后复发的卵巢癌患者，随机分为联合组（26例）和对照组（21例）。联合组口服足叶乙甙联合卡铂腹腔热灌注，对照组仅口服足叶乙甙，观察和比较两组的临床疗效和毒副反应。结果联合组的治疗总有效率和总生存时间显著优于对照组（61.5％vs.28.6％；13.0月vs.9.5月）；但其白细胞下降和腹痛的发生率均显著高于对照组（65.4％vs.33.3％；34.6％vs.4.8％）。结论口服足叶乙甙联合卡铂腹腔热灌注治疗多线化疗后复发性卵巢癌较单纯口服足叶乙甙更加有效，虽白细胞下降和腹痛的发生率更高但均可控，值得进一步研究和推广。

Clinical Study on the Oral Etoposide plus Hyperthermic Intraperitoneal Chemotherapy with Carboplatin for Recurrent Ovarian Cancer Patients after Multiline Chemotherapy

Objective To investigate the clinical efficacy and safety of oral Etoposide plus hyperthermic intraperitoneal chemotherapy with carboplatin in the treatment of recurrent ovarian cancer after multiline chemotherapy. Methods From January 2010 to August 2013, twenty six patients with recurrent ovarian cancer after multiline chemotherapy were treated with Oral Etoposide plus hyperthermic intraperitoneal chemotherapy with carboplatin, which was named the combined group;while twenty one patients with recurrent ovarian cancer after multiline chemotherapy were only treated with Oral Etoposide, which was named the control group. The clinical efficacy and incidence rates of adverse effects were observed and compared between the two groups. Results The overall response rate and overall survival time of the combined group were significantly higher or longer than those of the control group （61.5%vs. 28.6%;13.0 vs. 9.5month）;while the incidence rates of leucopenia and abdominal pain were both markedly higher in the combined group than in the control group（65.4%vs. 33.3%;34.6%vs. 4.8%）. Conclusion Oral Etoposide plus hyperthermic intraperitoneal chemotherapy with carboplatin was more effective than Oral Etoposide alone in the treatment of recurrent ovarian cancer after multiline chemotherapy. Although the incidence rates of leucopenia and abdominal pain were higher, both could be controlled, so it was still worth being popularized.